U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseaseGuruFocus · 1 day ago
Contrasting Chindata Group (NASDAQ:CD) & XP (NASDAQ:XP)Defense World · 5 days ago
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026GuruFocus · Oct 17, 2026
Chaince Securities, LLC to Serve as Exclusive Sales Agent for CL Workshop Group Limited's (NASDAQ: NWGL) Up to US$200 Million At-the-Market Offering ProgramGlobeNewsWire · Oct 15, 2026
Comparing Chindata Group (NASDAQ:CD) and B. Riley Financial (NASDAQ:RILY)Defense World · Oct 13, 2026
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseaseGuruFocus · Oct 11, 2026Chaince Digital Holdings Inc. engages in providing financial and advisory services in the North America, Greater China, Southeast Asia, Hong Kong, Singapore, Malaysia, and the United States. The company offers industry advisory and consulting services, such as corporate restructuring, capital markets preparation, regulatory compliance, and business expansion strategies; IPO-related financial advisory and consulting services, including transaction structuring, preparation for regulatory filings, coordination with underwriters and professional advisors, and strategic capital markets advisory; and private investment in public equity advisory and placement-related services comprising identifying potential investors, assisting in transaction structuring, and coordinating the placement process. It also provides transaction execution and brokerage, clearing-related brokerage, referral, and escrow agent services.